PROSTATE CANCER TRANSATLANTIC CONSORTIUM (CaPTC)
The Prostate Cancer Transatlantic Consortium (CaPTC) was formed in 2005 to address the globally disproportionate burden of prostate cancer among Black men. CaPTC is an open consortium comprising a team of prostate cancer scientists, clinicians, survivors, and advocates from North America, Europe, the Caribbean Islands, and West Africa.
CaPTC’s research goals are to:
- explore and quantify the magnitude of prostate cancer morbidity and mortality variance among Black men;
- explore the genetic and environmental etiology of this variance, using valid and reliable instruments and biomarkers; and
- develop ethnically sensitive, targeted approaches that will eliminate globally the prostate cancer disparities of Black men through modifiable risk factors associated with prostate cancer.
AFRICAN CARIBBEAN CANCER CONSORTIUM (AC3)
The African-Caribbean Cancer Consortium was formed in May 2006 to further the study of viral, genetic, environmental and lifestyle risk factors for cancer in populations of African descent.Camille Ragin PhD, MPH is responsible for the establishment and development of the consortium. A growing number of dedicated researchers based in the United States, Africa and the Caribbean have joined.
Our Mission – To study viral, genetic, environmental, and lifestyle factors for cancer risk and outcomes in populations of African descent
Our Vision – The AC3 will be a broad-based resource for education, training and research on etiology, screening, prevention, treatment and survivor-ship related to cancer in populations of African descent.
Our Goals
- Build knowledge, capacity and infrastructure
- Advance the science of cancer prevention and control in populations of African ancestry